Seroprevalence of Epstein-Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
26091801
DOI
10.1007/s10620-015-3764-z
PII: 10.1007/s10620-015-3764-z
Knihovny.cz E-zdroje
- Klíčová slova
- Azathioprine, Cytomegalovirus, Epstein–Barr virus, Immunosuppressive therapy, Inflammatory bowel disease, Infliximab,
- MeSH
- azathioprin škodlivé účinky MeSH
- Crohnova nemoc diagnóza farmakoterapie epidemiologie imunologie MeSH
- cytomegalovirové infekce diagnóza epidemiologie imunologie virologie MeSH
- dítě MeSH
- imunokompromitovaný pacient MeSH
- imunosupresiva škodlivé účinky MeSH
- infekce virem Epsteina-Barrové diagnóza epidemiologie imunologie virologie MeSH
- infliximab škodlivé účinky MeSH
- lidé MeSH
- logistické modely MeSH
- mladiství MeSH
- multivariační analýza MeSH
- odds ratio MeSH
- oportunní infekce diagnóza epidemiologie imunologie virologie MeSH
- polyomavirové infekce diagnóza epidemiologie imunologie virologie MeSH
- předškolní dítě MeSH
- prevalence MeSH
- průřezové studie MeSH
- rizikové faktory MeSH
- séroepidemiologické studie MeSH
- sérologické testy MeSH
- ulcerózní kolitida diagnóza farmakoterapie epidemiologie imunologie MeSH
- věkové faktory MeSH
- virová nálož MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika epidemiologie MeSH
- Názvy látek
- azathioprin MeSH
- imunosupresiva MeSH
- infliximab MeSH
BACKGROUND: Young age and thiopurine therapy are risk factors for lymphoproliferative disease among patients with inflammatory bowel disease (IBD). AIMS: The aims of this study were to evaluate the prevalence of seropositivity for the Epstein-Barr virus (EBV) and human cytomegalovirus (CMV) among children and adolescents with IBD, to assess the viral load of EBV, CMV, and BK and JC polyomaviruses (BKV, JCV) in these patients, and to assess the influence of different therapeutic regimens on seroprevalence and viral load. METHODS: Children who had been followed in our center were tested for EBV, CMV, BKV, and JCV in a cross-sectional study. One hundred and six children were included who had Crohn's disease (68%), ulcerative colitis (29%), and unclassified IBD (3%). RESULTS: We found that 64% of patients were EBV seropositive. The proportion of EBV seropositive patients increased during childhood. Azathioprine therapy (p = 0.003) was associated with EBV seropositivity in a multiple logistic regression model, after adjusting for gender, age, and disease activity at determination. We found a significant association between the number of polymerase chain reaction copies and infliximab dose (p = 0.023). We did not find any significant association between CMV serology and CMV, BKV, or JCV viral load, or any other therapeutic regimen or clinical characteristics. CONCLUSIONS: Treatment with azathioprine appears to be a risk factor for early EBV seropositivity in children with IBD, and the infliximab dose was associated with a higher EBV viral load.
Zobrazit více v PubMed
Gastroenterology. 2002 Jan;122(1):72-7 PubMed
Arthritis Rheum. 2006 Mar;54(3):692-701 PubMed
J Clin Microbiol. 1999 Jan;37(1):132-6 PubMed
Gut. 2005 Aug;54(8):1121-5 PubMed
J Neurovirol. 2012 Feb;18(1):55-61 PubMed
PLoS One. 2013 May 22;8(5):e64921 PubMed
Gut. 2008 Dec;57(12):1639-41 PubMed
N Engl J Med. 2005 Jul 28;353(4):362-8 PubMed
Aliment Pharmacol Ther. 2014 Jan;39(2):231-2 PubMed
Virology. 2013 Mar 15;437(2):63-72 PubMed
World J Gastroenterol. 2008 May 14;14(18):2912-4 PubMed
Am J Gastroenterol. 2011 Nov;106(11):2001-8 PubMed
J Med Virol. 2013 Apr;85(4):716-22 PubMed
Leuk Lymphoma. 2008 Jun;49(6):1028-41 PubMed
J Pediatr Gastroenterol Nutr. 2009 Mar;48(3):386-8 PubMed
Leukemia. 1998 Dec;12(12):2006-14 PubMed
J Stat Softw. 2010 Aug;36(2):null PubMed
Inflamm Bowel Dis. 2007 Jul;13(7):896-902 PubMed
Clin Infect Dis. 2006 Nov 1;43(9):1143-51 PubMed
Clin Microbiol Rev. 2010 Apr;23(2):350-66 PubMed
Enferm Infecc Microbiol Clin. 2005 Aug-Sep;23(7):424-37 PubMed
J Clin Virol. 2005 Sep;34(1):52-62 PubMed
J Pediatr. 2011 Nov;159(5):808-12 PubMed
J Crohns Colitis. 2014 Jun;8(6):443-68 PubMed
J Infect Dis. 2013 Oct 15;208(8):1286-93 PubMed
Aliment Pharmacol Ther. 2013 Nov;38(10):1248-54 PubMed
J Virol Methods. 2002 May;103(1):51-6 PubMed
J Crohns Colitis. 2014 Jan;8(1):31-44 PubMed
Int J Cancer. 2008 Oct 15;123(8):1917-23 PubMed
Lancet. 2009 Nov 7;374(9701):1617-25 PubMed
Inflamm Bowel Dis. 2013 May;19(6):1156-63 PubMed
Am J Gastroenterol. 2010 Oct;105(10):2299-301 PubMed
Blood. 2001 Mar 1;97(5):1165-71 PubMed
Inflamm Bowel Dis. 2013 Jul;19(8):1710-6 PubMed
Med Sci Monit. 2004 Nov;10(11):RA247-54 PubMed
